Scalper1 News
Big-cap biotech Gilead Sciences (GILD) was up 1% in midday trading on the stock market today, earlier touching a new high above 99, after it won a dispute with Roche over rights to its blockbuster hepatitis C drug, which separately was endorsed by the U.K.’s cost-benefit authority. Roche (RHHBY) had claimed rights to the drug, Sovaldi, last year due to its partnership with Pharmasset, which developed Sovaldi before Gilead acquired Pharmasset in Scalper1 News
Scalper1 News